Psilocybin compound achieves two positive Phase 3 results in treating depression - potential breakthrough in CNS disorders.
Helus Pharma, based in Vancouver, BC, announced on February 26, 2026, the groundbreaking development that the first psilocybin compound has successfully obtained two positive Phase 3 results for treating treatment-resistant depression. This significant achievement could mark a transformative change in the approach to managing depression. This breakthrough holds the promise of offering a new treatment option for patients struggling with depression.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments